Absci Corp - רווח נקי למניה ב-12 החודשים האחרונים ABSI

Absci (ABSI) is developing IT biotechnology by creating antibodies via neural networks, while the business remains in a stage of active capital expenditure. This chart illustrates the asset's market value, reflecting the 15.60 metric. Sean McClain successfully integrates bioengineering with AI, effectively attracting the largest pharmaceutical players and creating cutting-edge platforms for the synthesis of new medications.

The annual growth rate of net income per share determines the fundamental stability of cash flow and the company's ability to maintain payouts. The YoY percentage growth dynamics of earnings per share over 12 months are calculated as the ratio of current EPS to the value of the same period last year. This metric measures the efficiency of business scaling while excluding random market fluctuations. For Absci (ABSI), this indicator reflects the monetization of its generative antibody design AI platform and the capitalization of unique biological data.